Sarilumab
- Generic Name
- Sarilumab
- Brand Names
- Kevzara
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1189541-98-7
- Unique Ingredient Identifier
- NU90V55F8I
- Background
Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approva...
- Indication
Sarilumab is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs); and adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tole...
- Associated Conditions
- Polymyalgia Rheumatica (PMR), Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 16
- Registration Number
- NCT04008069
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis
- Conditions
- Interventions
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2024-12-17
- Target Recruit Count
- 21
- Registration Number
- NCT03770273
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study to Assess Sarilumab in Halting Progression of Morphea
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2021-09-08
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT03679845
- Locations
- 🇺🇸
CURTIS (Massachusetts General Hospital), Boston, Massachusetts, United States
Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 690
- Registration Number
- NCT03564340
- Locations
- 🇺🇸
The General Hospital Corporation d/b/a Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇬🇧University College London Hospitals, London, England, United Kingdom
Measurement of the Structural Efficacy in Active RA Patients Treated With Sarilumab in Combination With MTX and Naive to Biologics
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Gaylis, Norman B., M.D.
- Target Recruit Count
- 20
- Registration Number
- NCT03535402
- Locations
- 🇺🇸
AARDS Research, Inc, Aventura, Florida, United States
Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT03449758
- Locations
- 🇫🇷
Investigational Site Number 250014, Caen, France
🇫🇷Investigational Site Number 250006, Besancon, France
🇫🇷Investigational Site Number 250016, Bordeaux, France
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
- Conditions
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 400
- Registration Number
- NCT03414502
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 102
- Registration Number
- NCT02776735
- Locations
- 🇨🇦
Investigational Site Number : 1240112, Montréal, Quebec, Canada
🇨🇱Investigational Site Number : 1520016, Concepcion, BiobÃo, Chile
🇫🇷Investigational Site Number : 2500040, Paris, France
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
- Conditions
- Interventions
- Other: No systemic corticosteroidOther: No antiviral agent for COVID-19Other: No immune modulation for COVID-19Drug: Standard course macrolideOther: No antiviral agent for influenzaDrug: Local standard venous thromboprophylaxisOther: No immunoglobulinOther: No simvastatinOther: No cysteamineOther: No Immune Modulator for InfluenzaOther: No vitamin COther: No antiplateletProcedure: Clinician-preferred mechanical ventilation strategyOther: No renin-angiotensin system inhibitorOther: No endothelial modulatorDrug: CeftriaxoneDrug: Moxifloxacin or LevofloxacinDrug: Extended course macrolideDrug: Fixed-duration HydrocortisoneDrug: Five-days oseltamivirDrug: Lopinavir / RitonavirBiological: Convalescent plasmaDrug: Angiotensin converting enzyme inhibitorDrug: Nirmatrelvir/ritonavirDrug: Therapeutic dose anticoagulationProcedure: Protocolised mechanical ventilation strategyDrug: Interferon beta-1aDrug: Vitamin CDrug: SimvastatinDrug: AspirinDrug: EritoranDrug: CysteamineDrug: ImatinibDrug: Shock-dependent hydrocortisoneDrug: Ten-days oseltamivirDrug: P2Y12 inhibitorDrug: Angiotensin Receptor BlockersDrug: Conventional low dose thromboprophylaxisBiological: Delayed administration of convalescent plasmaDrug: Piperacillin-tazobactamDrug: HydroxychloroquineDrug: AnakinraDrug: ApremilastDrug: BaricitinibDrug: RemdesivirDrug: Fixed-duration higher dose HydrocortisoneDrug: Hydroxychloroquine + lopinavir/ritonavirDrug: Intermediate dose thromboprophylaxisDrug: Nirmatrelvir/ritonavir + remdesivirDrug: ARB + DMX-200Drug: CeftarolineDrug: Baloxavir MarboxilDrug: TocilizumabDrug: Amoxicillin-clavulanateDrug: Fixed-duration dexamethasoneDrug: Five-days oseltamivir + baloxavir marboxilDrug: Continuation of therapeutic dose anticoagulationDrug: IvermectinDrug: SarilumabDrug: Ten-days oseltamivir + baloxavir marboxil
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- UMC Utrecht
- Target Recruit Count
- 20000
- Registration Number
- NCT02735707
- Locations
- 🇨🇦
Toronto Western Hospital, Toronto, Ontario, Canada
🇺🇸University of Illinois Health, Chicago, Illinois, United States
🇦🇺Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia
A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)
- Conditions
- Interventions
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 91
- Registration Number
- NCT02373202
- Locations
- 🇯🇵
Investigational Site Number 392039, Fukuoka-Shi, Japan
🇯🇵Investigational Site Number 392006, Sasebo-Shi, Japan
🇯🇵Investigational Site Number 392023, Takaoka-Shi, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.